Can wearable glucose monitors reveal hidden risks in dialysis patients with diabetes?

NCT ID NCT07790276

Knowledge-focused Sponsor: Elaine Chow Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study follows 100 adults with diabetes who are on peritoneal dialysis or about to start it. Researchers use a continuous glucose monitor to track blood sugar levels over time. They will look for links between glucose patterns and health events like hospitalizations, heart problems, and death over 12 months. The goal is to see if this monitoring method offers better insight than traditional blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitoring system (Sibionics GS3 CGM)
What this could lead to
If it works, this could improve how doctors manage blood sugar in people with diabetes on peritoneal dialysis, potentially reducing hospitalizations and heart problems.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to everyone, and the device may have accuracy issues in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Stage 5 CKD patients 1. who have received PD for at least 3 months, OR 2. who are planned for PD within the next 3 months. 2. Age 18-80 years old 3. Known history of type 1 or type 2 diabetes for at least 3 months 4. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study. 5. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices. 6. Willingness to abstain from swimming during their participation in the measurement phase. 7. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate. 8. Written informed consent to participate in the study provided by the patient. Exclusion criteria: 1. Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months 2. Life expectancy \<6 months 3. Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites 4. HbA1c \> 11% at enrolment 5. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential. 6. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study. 7. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff. 8. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device. 9. Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study. 10. Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.